This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Williams, S. A. Articles by McConkey, D. J. Search for Related Content PubMed PubMed Citation Articles by Williams, S. A. Articles by McConkey, D. J.

The Proteasome Inhibitor Bortezomib Stabilizes a Novel Active Form of p53 in Human LNCaP-Pro5 Prostate Cancer Cells¹

Department of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

Advanced prostate cancer is resistant to current therapeutic strategies. Bortezomib (Velcade; previously called PS-341) is a potent and specific inhibitor of the 26S proteasome that is currently in clinical trials for treatment of various malignancies, including prostate cancer. We investigated the effects of bortezomib on p53 in the LNCaP-Pro5 prostate cancer cell line. Bortezomib induced strong stabilization of p53, but it did not promote phosphorylation on serines 15 and 20, and p53 remained bound to its inhibitor, mdm2. Nonetheless, bortezomib stimulated p53 translocation to the nucleus (not mitochondria) and enhanced p53 DNA binding, accumulation of p53-dependent transcripts, and activation of a p53-responsive reporter gene. Furthermore, stable LNCaP-Pro5 transfectants of LNCaP-Pro5 expressing the p53 inhibitor human papillomavirus-E6 displayed reduced bortezomib-induced p53 activation and cell death. Together, our data demonstrate that bortezomib stimulates p53 activation via a novel mechanism.

This article has been cited by other articles:

				K. Zhu, W. Chan, J. Heymach, M. Wilkinson, and D. J. McConkey Control of HIF-1{alpha} Expression by eIF2{alpha} Phosphorylation-Mediated Translational Repression Cancer Res., March 1, 2009; 69(5): 1836 - 1843. [Abstract] [Full Text] [PDF]

				S. Dayal, A. Sparks, J. Jacob, N. Allende-Vega, D. P. Lane, and M. K. Saville Suppression of the Deubiquitinating Enzyme USP5 Causes the Accumulation of Unanchored Polyubiquitin and the Activation of p53 J. Biol. Chem., February 20, 2009; 284(8): 5030 - 5041. [Abstract] [Full Text] [PDF]

				E. Colado, S. Alvarez-Fernandez, P. Maiso, J. Martin-Sanchez, M. B. Vidriales, M. Garayoa, E. M. Ocio, J. C. Montero, A. Pandiella, and J. F. San Miguel The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype Haematologica, January 1, 2008; 93(1): 57 - 66. [Abstract] [Full Text] [PDF]

				D. Yu, M. Carroll, and A. Thomas-Tikhonenko p53 status dictates responses of B lymphomas to monotherapy with proteasome inhibitors Blood, June 1, 2007; 109(11): 4936 - 4943. [Abstract] [Full Text] [PDF]

				S. E. Canfield, K. Zhu, S. A. Williams, and D. J. McConkey Bortezomib inhibits docetaxel-induced apoptosis via a p21-dependent mechanism in human prostate cancer cells. Mol. Cancer Ther., August 1, 2006; 5(8): 2043 - 2050. [Abstract] [Full Text] [PDF]

				G. Achanta, A. Modzelewska, L. Feng, S. R. Khan, and P. Huang A Boronic-Chalcone Derivative Exhibits Potent Anticancer Activity through Inhibition of the Proteasome Mol. Pharmacol., July 1, 2006; 70(1): 426 - 433. [Abstract] [Full Text] [PDF]

				Z. Zhu, J. Ramos, K. Kampa, S. Adimoolam, M. Sirisawad, Z. Yu, D. Chen, L. Naumovski, and C. D. Lopez Control of ASPP2/53BP2L Protein Levels by Proteasomal Degradation Modulates p53 Apoptotic Function J. Biol. Chem., October 14, 2005; 280(41): 34473 - 34480. [Abstract] [Full Text] [PDF]

				D. Chauhan, T. Hideshima, C. Mitsiades, P. Richardson, and K. C. Anderson Proteasome inhibitor therapy in multiple myeloma Mol. Cancer Ther., April 1, 2005; 4(4): 686 - 692. [Abstract] [Full Text] [PDF]

				M. Nikrad, T. Johnson, H. Puthalalath, L. Coultas, J. Adams, and A. S. Kraft The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim Mol. Cancer Ther., March 1, 2005; 4(3): 443 - 449. [Abstract] [Full Text] [PDF]

				M. Lun, P. L. Zhang, N. Siegelmann-Danieli, T. M. Blasick, and R. E. Brown Intracellular Inhibitory Effects of Velcade Correlate with Morphoproteomic Expression of Phosphorylated-Nuclear Factor-{kappa}B and p53 in Breast Cancer Cell Lines Ann. Clin. Lab. Sci., January 1, 2005; 35(1): 15 - 24. [Abstract] [Full Text] [PDF]

				Q. Xu, M. Farah, J. M. Webster, and R. J.H. Wojcikiewicz Bortezomib rapidly suppresses ubiquitin thiolesterification to ubiquitin-conjugating enzymes and inhibits ubiquitination of histones and type I inositol 1,4,5-trisphosphate receptor Mol. Cancer Ther., October 1, 2004; 3(10): 1263 - 1269. [Abstract] [Full Text] [PDF]

				E. G. Mimnaugh, W. Xu, M. Vos, X. Yuan, J. S. Isaacs, K. S. Bisht, D. Gius, and L. Neckers Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity Mol. Cancer Ther., May 1, 2004; 3(5): 551 - 566. [Abstract] [Full Text] [PDF]